Your session is about to expire
← Back to Search
Vactosertib + Durvalumab for Bladder Cancer
Study Summary
This trial will test whether adding vactosertib to durvalumab will improve response rates in patients with urothelial cancers who haven't responded to anti-PD-1/PD-L1 treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had cancer spread to the lining of my brain and spinal cord.My organs and bone marrow are working well.I have or had an autoimmune or inflammatory disorder.My cancer came back after platinum-based treatment or I can't have platinum therapy.I have previously received anti-PD-(L)1 therapy.I have had another type of cancer in the past.I do not have an active infection like TB, hepatitis B or C, or HIV.You have a history of a weak immune system that doesn't work well to fight off infections.I am fully active or restricted in physically strenuous activity but can do light work.I do not have any uncontrolled illnesses like infections or heart failure.I don't have any major side effects from cancer treatment except for hair loss or skin changes.My cancer originates from the urinary system and cannot be removed by surgery.My cancer can be measured by scans.My body weight is over 30 kg.You have had a transplant of an organ donated by someone else in the past.
- Group 1: Vactosertib+Durvalumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what medical conditions is Vactosertib(TEW-7197)/ Durvalumab most beneficial?
"Patients with unresectable stage III non-small cell lung cancer, as well as those diagnosed with untreated metastatic ureteral urothelial carcinoma can benefit from the combination of Vactosertib (TEW-7197) and Durvalumab."
Are there still openings to join this clinical research?
"This trial has already finished recruitment. The original posting on October 15th 2021 was the most recently updated to September 22nd, 2021. For those seeking other studies involving urothelial carcinoma recurrent or Vactosertib (TEW-7197)/ Durvalumab, there are presently 2506 and 343 trials respectively actively enrolling participants."
Has the FDA given their stamp of approval to Vactosertib(TEW-7197)/ Durvalumab?
"Based on our team's assessment, Vactosertib(TEW-7197)/ Durvalumab received a rating of 2 due to the lack of efficacy data in Phase 2 trials. However, there is some evidence that suggests this drug is safe for use."
What is the total population size for this research endeavor?
"At this juncture, the trial is not in need of patients. The first announcement was made on October 15th 2021 and it's been revised most recently on September 22nd 2021. For those looking for alternate studies relating to urothelial carcinoma recurrent there are 2506 clinical trials recruiting participants; 343 studies concerning Vactosertib (TEW-7197)/Durvalumab are also actively seeking candidates."
Are there any records of collaborative research between Vactosertib(TEW-7197) and Durvalumab?
"Presently, there are 343 active clinical trials researching the efficacy of combining Vactosertib(TEW-7197) and Durvalumab. This includes 52 Phase 3 studies mostly situated in Cordoba, Texas but with a total of 12969 sites conducting such research across the world."
Share this study with friends
Copy Link
Messenger